Related Experiment Video
Updated: Jul 9, 2026

Retroviral Scanning: Mapping MLV Integration Sites to Define Cell-specific Regulatory Regions
Published on: May 28, 2017
Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced
Antonio Ruiz-Vela1, Mohit Aggarwal, Paloma de la Cueva
1Lymphoma Group, Department of Molecular Pathology, Biotechnology Program, Spanish National Cancer Centre, Madrid, Spain. antonio.ruizvela@universia.es
Abstract:
Aberrant inhibition of B-cell receptor (BCR)-induced programmed cell death pathways is frequently associated with the development of human auto-reactive B-cell lymphomas. Here, we integrated loss-of-function, genomic, and bioinformatics approaches for the identification of oncogenic mechanisms linked to the inhibition of BCR-induced clonal deletion pathways in human B-cell lymphomas. Lentiviral (HIV)-based RNA interference screen identified MCL1 as a key survival molecule linked to BCR signaling. Loss of MCL1 by RNA interference rendered human B-cell lymphomas sensitive to BCR-induced programmed cell death. Conversely, MCL1 overexpression blocked programmed cell death on BCR stimulation. To get insight into the mechanisms of MCL1-induced survival and transformation, we screened 41 000 human genes in a genome-wide gene expression profile analysis of MCL1-overexpressing B-cell lymphomas. Bioinformatic gene network reconstruction illustrated reprogramming of relevant oncoproteins within beta-catenin-T-cell factor signaling pathways induced by enforced MCL1 expression. Overall, our findings not only illustrate MCL1 as an aberrantly expressed reprogramming oncoprotein in follicular lymphomas but also highlight MCL1 as key therapeutic target.
Insights
Aberrant inhibition of B-cell receptor (BCR) signaling promotes lymphoma development. Targeting MCL1, a key survival protein, restores BCR-induced cell death, offering a potential therapeutic strategy for B-cell lymphomas.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Aberrant inhibition of B-cell receptor (BCR)-induced programmed cell death is linked to human auto-reactive B-cell lymphomas.
- Understanding the oncogenic mechanisms driving these lymphomas is crucial for developing effective therapies.
Purpose of the Study:
- To identify oncogenic mechanisms that inhibit BCR-induced clonal deletion pathways in human B-cell lymphomas.
- To investigate the role of MCL1 in B-cell lymphoma survival and transformation.
Main Methods:
- Utilized loss-of-function, genomic, and bioinformatics approaches.
- Conducted an HIV-based RNA interference screen to identify key survival molecules.
- Performed genome-wide gene expression profiling of MCL1-overexpressing B-cell lymphomas.
Main Results:
- Identified MCL1 as a critical survival molecule in BCR signaling; its loss sensitized lymphomas to BCR-induced cell death.
- MCL1 overexpression inhibited programmed cell death upon BCR stimulation.
- Bioinformatic analysis revealed MCL1-induced reprogramming of oncoproteins within beta-catenin-T-cell factor signaling pathways.
Conclusions:
- MCL1 is an aberrantly expressed oncoprotein in follicular lymphomas.
- MCL1 plays a key role in lymphoma cell survival and transformation.
- MCL1 represents a significant therapeutic target for B-cell lymphomas.
Related Concept Videos
Non-LTR Retrotransposons
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers

